Description
G17DT-Irinotecan is used in the treatment of metastatic colorectal cancer (mCRC) as second-line therapy after failure with fluoropyrimidine-based regimens. It has shown efficacy when combined with other agents such as leucovorin and 5-fluorouracil.
Mechanism of Action
G17DT-Irinotecan is a prodrug that, after administration, is converted to its active metabolite SN-38, which binds topoisomerase I and inhibits DNA replication.
Side Effects
Neutropenia; Diarrhea; Nausea and vomiting; Fatigue
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT02118064
Phase 2
Completed
Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma